论文部分内容阅读
目的:探讨西施泰与吡柔比星联合灌注减少膀胱灌注化疗所致并发症的效果。方法:从2009～2011年来我院治疗的200患者中挑选符合条件的120例患者,将其随机分为对照组和研究组,每组60例,研究组给予联合灌注西施泰与吡柔比星,对照组仅仅给予灌注吡柔比星。治疗后,比较两组膀胱疼痛直观模拟分级(VAS)评分,评价其疗效。结果:对照组治疗前后的VAS评分差值及改善率为0.69±1.81与(20.58±87.24)%,研究组治疗前后的VAS评分差值及改善率为2.23±1.71与(92.93±14.75)%,两组评分差值显著,P<0.05,具有统计学意义。结论:西施泰与吡柔比星联合灌注能够减少膀胱疼痛直观模拟分级评分,可以较为迅速、持续地减缓疼痛,治疗效果甚佳,值得在临床上广泛推广。
Objective: To investigate the effect of combination of cisplatin and pirarubicin to reduce the complications caused by bladder infusion chemotherapy. Methods: From 2009 to 2011 to treat patients with 200 patients selected eligible 120 patients were randomly divided into the control group and the study group, 60 cases in each group, the study group was given combination of Cisplatin and pirarubicin , Control group only given perfusion of pirarubicin. After treatment, visual analogue scale (VAS) score of bladder pain were compared to evaluate the curative effect. Results: The differences and improvement rates of VAS scores before and after treatment in control group were 0.69 ± 1.81 and (20.58 ± 87.24)%, respectively. The differences and improvement rates of VAS scores before and after treatment in study group were 2.23 ± 1.71 and (92.93 ± 14.75)%, respectively The difference between the two groups was significant, P <0.05, with statistical significance. Conclusion: Combination of XST and Pirarubicin can reduce the direct visual analogue grading of bladder pain, which can reduce the pain more rapidly and sustainably. The treatment effect is very good and worthy of widespread application in clinic.